About Mereo BioPharma Group
Mereo BioPharma Group (LSE:0A9G), (NASDAQ:MREO) focuses on developing and commercializing innovative therapeutics in areas of significant unmet medical need, particularly rare diseases and oncology. This company is exclusively listed on the NASDAQ stock exchange under the ticker symbol MREO, concentrating its efforts on advancing a diverse and specialized pipeline. Mereo's projects aim to address critical gaps in treatment options for patients suffering from a variety of serious diseases, with the objective of improving patient outcomes and quality of life. The company engages in rigorous research and development, partnering with healthcare professionals and organizations to bring novel medicines to market. Through strategic collaborations and a steadfast commitment to innovation, Mereo BioPharma Group seeks to establish a leading position in the biopharmaceutical industry, delivering value to patients, healthcare systems, and its stakeholders.
Snapshot
Operations
Products and/or services of Mereo BioPharma Group
- BPS-804 (Setrusumab) for Osteogenesis Imperfecta - A monoclonal antibody aimed at treating brittle bone disease by reducing bone fractures and promoting bone formation and strength.
- Alvelestat (MPH-966) for Alpha-1 Antitrypsin Deficiency (AATD) - An orally available inhibitor targeting neutrophil elastase for the treatment of AATD-associated lung disease.
- Etidronate for Osteogenesis Imperfecta in Children - A bisphosphonate drug intended to increase bone density and reduce the risk of fractures in pediatric patients.
- NAV-5001 for Diagnostic Imaging in Parkinson's Disease - A radiopharmaceutical agent aimed at improving the detection and management of Parkinsonian syndromes through superior imaging techniques.
- Acumapimod (BCT-197) for Acute Exacerbations of COPD - An orally administered p38 MAP kinase inhibitor designed to reduce inflammation in patients with chronic obstructive pulmonary disease.
- Leflutrozole for Breast Cancer - A novel aromatase inhibitor being explored for its potential to treat hormone-sensitive breast cancer by reducing estrogen levels.
Mereo BioPharma Group executive team
- Dr. Denise Vera Scots-Knight Ph.D.Co-Founder, CEO & Executive Director
- Mr. Charles Edward SermonCo-Founder, General Counsel, Business Development & Company Secretary
- Ms. Christine Fox CPAChief Financial Officer
- Dr. John P. Richard M.B.A.Co-Founder & Chief Business Officer
- Dr. John A. Lewicki Ph.D.Chief Scientific Officer
- Dr. Jackie ParkinSenior VP & Therapeutic Head
- Ms. Alexandra Hughes-WilsonChief of Patient Access & Commercial Planning
- Mr. Bo KaraSenior VP and Head of Pharmaceutical Development & CMC